Migd-061: __full__

The "MIGD" prefix is a label used by the major studio MOODYZ to categorize its "Great" series, which typically focuses on high-definition (HD) releases featuring various adult themes. Like many titles from the late 2000s, this release marked a period where the industry began transitioning to digital and higher-definition formats to meet evolving consumer expectations for visual quality. Identification and Availability

| Species | Study | No‑Observed‑Adverse‑Effect Level (NOAEL) | Findings | |---------|-------|-------------------------------------------|----------| | | Oral (0.5‑100 mg/kg/day) | 30 mg/kg/day | No clinical signs; mild hepatocellular vacuolation at 100 mg/kg (reversible). | | Dog (90‑day) | Oral (1‑50 mg/kg/day) | 10 mg/kg/day | No mortality; transient increase in serum bilirubin at 50 mg/kg (resolved). | | Genotoxicity | Ames, Chromosome Aberration, Micronucleus | Negative across assays. | | Cardiac safety | hERG assay (IC₅₀ ≈ > 30 µM) | No QTc prolongation in telemetry‑monitored dogs (up to 20 mg/kg). | | Reproductive toxicity | Rat embryo‑fetal (GD 6‑15) | 20 mg/kg/day | No teratogenicity; slight decrease in fetal weight at highest dose (statistically non‑significant). |

| Model | Dosing Regimen | Endpoints & Results | |-------|----------------|---------------------| | | 30 mg/kg PO QD, 21 days | Tumor growth inhibition (TGI) = 62 % vs. vehicle; enhanced CD8⁺ T‑cell infiltration (↑ 2.3‑fold). | | Humanized NSG mouse xenograft (A549) + anti‑PD‑1 | MIGD‑061 15 mg/kg PO QD + pembrolizumab 10 mg/kg IP Q3D | Combination TGI = 84 % (vs. 48 % for pembrolizumab alone). | | SOD1‑G93A ALS mouse model | 10 mg/kg PO BID, started at P60 | Delayed onset of motor decline by 12 days; ↑ survival median + 8 days (p = 0.03). | | Dengue virus (DENV‑2) in AG129 mice | 25 mg/kg PO BID, 5 days post‑infection | Viral load in serum ↓ 1.7 log₁₀; survival 70 % vs. 30 % in control. | migd-061

The ISR orchestrates cellular adaptation to amino‑acid deprivation, oxidative stress, and viral infection. Hyper‑activation of GCN2 has been linked to tumor immune evasion (via PD‑L1 up‑regulation), chronic neurodegeneration, and viral replication. Consequently, selective GCN2 inhibition is being explored for oncology, neuro‑inflammation, and infectious disease.

MIGD‑061 is an internally‑coded candidate from , a biotech spin‑out of the University of Zurich that specializes in “modulators of the Integrated Stress Response (ISR)”. The program was first disclosed in a 2023 patent filing (WO 2023/184567) and later presented as a poster at the American Association for Cancer Research (AACR) 2024 meeting. The molecule is described as a potent, selective, orally bioavailable inhibitor of the protein‑protein interaction between GCN2 (EIF2AK4) and its activator protein GCN2‑Interacting Protein (GIP) , positioning it as a first‑in‑class ISR‑targeted therapeutic. The "MIGD" prefix is a label used by

Total Addressable Market (TAM) for the combined indications exceeds , with

– MIGD‑061 demonstrates a favorable pre‑clinical toxicology profile with a therapeutic index > 30 × the projected clinical exposure (Cmax at 30 mg). The most consistent signal is a mild, reversible hepatic enzyme elevation , which appears dose‑related but manageable with routine monitoring. | | Dog (90‑day) | Oral (1‑50 mg/kg/day)

Users searching for this code often encounter it on specialized databases such as the JAV Database or JAVLibrary , which provide metadata including actress profiles, user ratings, and official distribution links.

| Indication | TAM (2026, $B) | Current Standard of Care | Competitive Edge of MIGD‑061 | |------------|----------------|--------------------------|-------------------------------| | | 45 | PD‑1/PD‑L1 mAbs (pembrolizumab, nivolumab) ± CTLA‑4 | First‑in‑class ISR modulator ; potential to convert “cold” tumours to “hot” via immune‑reprogramming. | | Amyotrophic Lateral Sclerosis (ALS) | 6 | Riluzole, edaravone (limited efficacy) | Oral, disease‑modifying mechanism distinct from excitotoxicity; Orphan designation may accelerate path to market. | | Flavivirus infections (Dengue, Zika) | 1.2 (episodic) | Supportive care | Host‑targeted antiviral with high barrier to resistance. |

Published under the MOODYZ label, specifically within the MIGD series. Runtime: Approximately 120 minutes. Director: Katsuyuki Hasegawa. Context of the MIGD Series

| Trial | Design | Status (as of Apr 2026) | Key Findings | |-------|--------|--------------------------|--------------| | (Phase I, First‑in‑Human) | Open‑label, dose‑escalation (5‑100 mg QD) in healthy volunteers (n = 48) | Completed (Dec 2024) | - Safety: No SAEs; Grade 1‑2 AEs: headache (15 %), nausea (12 %), transient ALT↑ (3 %). - PK: Linear exposure; Cmax at 2‑3 h; t½ ≈ 7 h (human). - PD: Dose‑dependent reduction of p‑eIF2α in PBMCs; > 80 % inhibition at ≥ 30 mg. | | NCT05922389 (Phase I/II, Oncology) | 3 + 3 escalation (15‑60 mg QD) + expansion in advanced solid tumours (n = 68) receiving pembrolizumab | Ongoing (enrollment 2nd cohort) | - DLT: None reported at 30 mg; one Grade 3 ALT elevation at 60 mg (resolved). - Preliminary efficacy: 2 PRs (lung SCC, colorectal) and 5 SDs lasting ≥ 4 months in the 30 mg cohort (overall response rate ≈ 3 %). | | NCT06000112 (Phase I, ALS) | Randomized, double‑blind, 30 mg vs. placebo QD (n = 24) | Initiated (Feb 2025); interim analysis pending | - Primary endpoint: safety and tolerability. - Exploratory biomarker: CSF ATF4 levels trending down in treatment arm. |